A venture capital firm with offices in Canada was founded by a leading venture capital firm’s former healthcare investment team, who has a successful track record of identifying, building, and growing life science companies. The firm’s newest fund will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).

The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2020 and based in the US is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with check sizes between 5 – 10 million USD. The firm prefers to lead the financing rounds but is open to co-investing. The firm will consider opportunities globally.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, the firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises.

The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based investment firm was founded with a focus on early stage healthcare companies. The firm currently has 34 companies in their portfolio with 4 exits. The firm invests in all 4 life science sectors and the typical check size ranges from $100K – 500K and typically helps fill out existing rounds once there is a lead investor in-place. The firm generally seeks to make investments into emerging life science companies in Pre-Seed, Seed and Series A stages. The firm is US focused in terms of geographic preference, but will occasionally look outside of the US.

The firm invests across all life science verticals and is open to all 4 sectors. The firm looks for novel technologies in biotech, medtech, digital health therapeutics, and diagnostics. In terms of biotech companies, the firm focuses on biotechnology platforms rather than single asset biotech companies. The firm is agnostic to both subsector and indication and is open to both pre-clinical therapeutic companies as well as all three stages of medical devices.

The firm is open to all types of management teams, with a goal to democratize who gets funding in the life science space. The firm is looking for diversity in the management team to combine ideas and skill set. The firm prefers to co-invest rather than lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm that was established in 2015 and is headquartered in Western Europe. The firm will consider pre-seed investments but is primarily looking to participate in the Seed to Series A financings of early-stage companies with typical pre-money valuation usually between USD 5 million and USD 30 million. Average ticket size is USD 0.5 million. The firm currently participates in equity investments as well as convertible debt. The firm historically has made around ten new investments per year. The firm is focused on partnering with companies based in Western Europe but will consider global opportunities.

The firm is primarily interested in investing in companies in the medical technology and digital health sectors but will also consider those in the wearables and diagnostics sector as well. The firm is open to all modalities within the medical technology and digital health sectors but prefers diagnostic companies to be focused on devices rather than genomics or in vitro diagnostics. The firm will not consider investments in biotech or pharma companies. The firm prefers to invest in pre-market technologies with some proof of pre-clinical data available and will only invest in Class I and Class II (510k) medical devices, avoiding Class III (PMA). The firm will consider companies across all disease indications but prefers to avoid complex disease indications such as the oncology space.

The firm is open to working with both inexperienced and experienced management teams. The firm looks to work with management teams that are efficient and work well together. The firm will sometimes take a board seat as determined on a case-by-case basis. The firm normally prefers to co-invest but will occasionally take a lead role in investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early stage fund founded by a group of alumni from a leading university is based in the USA. The group currently has $100M, under management. The group focuses on Angel to Series B stage companies across various sectors, including pharmaceutical, medical device, services and tools, and digital health. The typical investment size is between $1M to $2M. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe.

The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed rounds and series A rounds. Historically, the fund has been active in life science companies developing innovative platform technologies and cross-disciplinary technologies.

The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

One of the leading fully integrated biopharmaceutical companies in China has established three integrated R&D centers, with locations in USA and China. The firm has built a market-leading product portfolio in China. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading innovative companies and research institutes. The firm is actively seeking for licensing/collaboration on development candidates with first-in-class or best-in-class potentials, and commercial products with substantial market opportunities in China and worldwide.

The firm is actively looking for innovative drug candidates in all stages in the therapeutic areas of Oncology, CNS, Autoimmune and Infectious disease, as well as a technology platform in Cell Therapy.

The firm is looking for companies with capacity and experience in implementing R&D plans. The firm is interested in assets from the US, Europe or other countries, and intends to introduce the product to the Chinese market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund in the process of raising USD 150 million will be used to invest in around ten to twelve early-stage startups. The fund will primarily look to participate in Series A fundraising but is open to earlier rounds as well. The firm will only participate in equity investments with an initial check size between USD 3 million and USD 7 million. The fund will primarily invest in companies that are based in the United States but is open to considering opportunities in Canada as well.

The firm is interested in investing in companies within the therapeutics, diagnostics, and medical technology sectors. The fund is modality agnostic and open to all companies within these sectors but will not consider investments in digital health. The firm will primarily seek to invest in therapeutics in the pre-clinical and Phase I stages of development as well as devices and diagnostics that are in development and clinical. The fund will invest in all classes of medical devices including Class II (510k) and Class III (PMA). The firm is disease agnostic and will consider companies across all indications including orphan diseases.

The firm prefers to work with experienced management teams that are made up of passionate and driven people developing great science. The fund is an active investor that will require a board seat and may act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.